LSE - Delayed Quote GBp
Indivior PLC (INDV.L)
As of 1:01 PM GMT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 7 | 7 |
| Avg. Estimate | 0.26 | 0.37 | 1.63 | 1.59 |
| Low Estimate | 0.14 | 0.28 | 1.49 | 1 |
| High Estimate | 0.33 | 0.46 | 1.75 | 2.02 |
| Year Ago EPS | 0.43 | 0.37 | 1.57 | 1.63 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 7 | 7 |
| Avg. Estimate | 260.43M | 266.15M | 1.16B | 1.1B |
| Low Estimate | 255M | 257.4M | 1.14B | 1.03B |
| High Estimate | 270M | 274.9M | 1.2B | 1.28B |
| Year Ago Sales | 293M | 284M | 1.09B | 1.16B |
| Sales Growth (year/est) | -11.11% | -6.29% | 5.83% | -4.82% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.28 | 0.41 | 0.4 | 0.41 |
| EPS Actual | 0.43 | 0.37 | 0.44 | 0.54 |
| Difference | 0.15 | -0.04 | 0.04 | 0.13 |
| Surprise % | 53.57% | -10.84% | 9.09% | 32.79% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.26 | 0.37 | 1.63 | 1.59 |
| 7 Days Ago | 0.31 | 0.32 | 1.6 | 1.57 |
| 30 Days Ago | 0.43 | 0.4 | 1.71 | 1.96 |
| 60 Days Ago | 0.47 | 0.44 | 1.73 | 2.03 |
| 90 Days Ago | 0.47 | 0.44 | 1.76 | 2.08 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 4 | 2 |
| Up Last 30 Days | -- | 1 | 1 | -- |
| Down Last 7 Days | 1 | 1 | 1 | 1 |
| Down Last 30 Days | 2 | 1 | 5 | 6 |
Growth Estimates
| CURRENCY IN USD | INDV.L | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -38.76% | -- | -- | 5.00% |
| Next Qtr. | 0.00% | -- | -- | 12.00% |
| Current Year | 3.92% | -- | -- | 2.10% |
| Next Year | -2.58% | -- | -- | 12.20% |
Upgrades & Downgrades
| Reiterates | Piper Sandler: Overweight to Overweight | 10/25/2024 |
| Maintains | Craig-Hallum: Buy to Buy | 10/11/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 10/11/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 9/13/2024 |
| Initiated | Piper Sandler: Overweight | 7/23/2024 |
| Maintains | Craig-Hallum: Buy to Buy | 7/10/2024 |
Related Tickers
HCM.L HUTCHMED (China) Limited
264.86
-0.05%
HIK.L Hikma Pharmaceuticals PLC
1,834.00
+0.82%
BXP.L Beximco Pharmaceuticals Limited
33.97
+9.58%
MKGAF Merck KGaA
147.65
-2.86%
6785.TWO Alar Pharmaceuticals Inc.
149.50
+3.10%
HLN.L Haleon plc
367.79
+0.57%
AQST Aquestive Therapeutics, Inc.
4.6400
+4.50%
AVDL Avadel Pharmaceuticals plc
10.72
-1.79%
BIOA BioAge Labs, Inc.
18.12
-0.93%
NBIX Neurocrine Biosciences, Inc.
117.62
+0.15%